Go Pro
→ Why I believe the AI market will split in Q4 (From The Oxford Club) (Ad)tc pixel Free CRON Stock Alerts

Cronos Group (CRON) Competitors

Cronos Group logo
C$4.81 -0.01 (-0.21%)
As of 09/23/2026 04:00 PM Eastern
Compare

CRON vs. APHA, BHC, MJN, CARA, and GUD

Should you buy Cronos Group stock or one of its competitors? Cronos Group's main competitors and comparable companies include Aphria (APHA), Bausch Health Companies (BHC), Cronos Group (MJN), Cara Operations (CARA), and Knight Therapeutics (GUD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cronos Group compare to Aphria?

Cronos Group (TSE:CRON) and Aphria (TSE:APHA) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

Cronos Group has higher earnings, but lower revenue than Aphria. Aphria is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cronos GroupC$179.09M9.90-C$32.78MC$0.1925.32
AphriaC$611.06M0.00-C$637.39M-C$2.01N/A

4.3% of Cronos Group shares are held by institutional investors. 46.4% of Cronos Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Cronos Group has a net margin of 38.95% compared to Aphria's net margin of 0.00%. Cronos Group's return on equity of 6.46% beat Aphria's return on equity.

Company Net Margins Return on Equity Return on Assets
Cronos Group38.95% 6.46% -3.73%
Aphria N/A N/A N/A

Cronos Group currently has a consensus target price of C$4.92, indicating a potential upside of 2.22%. Given Cronos Group's stronger consensus rating and higher possible upside, equities research analysts plainly believe Cronos Group is more favorable than Aphria.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cronos Group
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Aphria
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Cronos Group's average media sentiment score of 0.00 equaled Aphria'saverage media sentiment score.

Company Overall Sentiment
Cronos Group Neutral
Aphria Neutral

Summary

Cronos Group beats Aphria on 10 of the 12 factors compared between the two stocks.

How does Cronos Group compare to Bausch Health Companies?

Bausch Health Companies (TSE:BHC) and Cronos Group (TSE:CRON) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

9.7% of Bausch Health Companies shares are owned by institutional investors. Comparatively, 4.3% of Cronos Group shares are owned by institutional investors. 11.3% of Bausch Health Companies shares are owned by insiders. Comparatively, 46.4% of Cronos Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cronos Group has a consensus price target of C$4.92, indicating a potential upside of 2.22%. Given Cronos Group's stronger consensus rating and higher possible upside, analysts clearly believe Cronos Group is more favorable than Bausch Health Companies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bausch Health Companies
0 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Cronos Group
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Cronos Group has lower revenue, but higher earnings than Bausch Health Companies. Bausch Health Companies is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bausch Health CompaniesC$10.85B0.28-C$125.65M-C$2.94N/A
Cronos GroupC$179.09M9.90-C$32.78MC$0.1925.32

Cronos Group has a net margin of 38.95% compared to Bausch Health Companies' net margin of -12.02%. Bausch Health Companies' return on equity of 87.57% beat Cronos Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Bausch Health Companies-12.02% 87.57% 4.16%
Cronos Group 38.95%6.46%-3.73%

In the previous week, Bausch Health Companies had 7 more articles in the media than Cronos Group. MarketBeat recorded 7 mentions for Bausch Health Companies and 0 mentions for Cronos Group. Bausch Health Companies' average media sentiment score of 0.21 beat Cronos Group's score of 0.00 indicating that Bausch Health Companies is being referred to more favorably in the media.

Company Overall Sentiment
Bausch Health Companies Neutral
Cronos Group Neutral

Bausch Health Companies has a beta of 0.707626, suggesting that its share price is 29% less volatile than the broader market. Comparatively, Cronos Group has a beta of 1.29991, suggesting that its share price is 30% more volatile than the broader market.

Summary

Cronos Group beats Bausch Health Companies on 10 of the 16 factors compared between the two stocks.

How does Cronos Group compare to Cronos Group?

Cronos Group (CVE:MJN) and Cronos Group (TSE:CRON) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

Cronos Group has a net margin of 38.95% compared to Cronos Group's net margin of 0.00%. Cronos Group's return on equity of 6.46% beat Cronos Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Cronos GroupN/A N/A N/A
Cronos Group 38.95%6.46%-3.73%

In the previous week, Cronos Group's average media sentiment score of 0.00 equaled Cronos Group'saverage media sentiment score.

Company Overall Sentiment
Cronos Group Neutral
Cronos Group Neutral

Cronos Group has higher earnings, but lower revenue than Cronos Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cronos GroupN/AN/AN/AN/AN/A
Cronos GroupC$179.09M9.90-C$32.78MC$0.1925.32

4.3% of Cronos Group shares are held by institutional investors. 46.4% of Cronos Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Cronos Group has a consensus target price of C$4.92, suggesting a potential upside of 2.22%. Given Cronos Group's stronger consensus rating and higher possible upside, analysts clearly believe Cronos Group is more favorable than Cronos Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cronos Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Cronos Group
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Cronos Group beats Cronos Group on 8 of the 9 factors compared between the two stocks.

How does Cronos Group compare to Cara Operations?

Cara Operations (TSE:CARA) and Cronos Group (TSE:CRON) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

Cronos Group has a consensus target price of C$4.92, indicating a potential upside of 2.22%. Given Cronos Group's stronger consensus rating and higher possible upside, analysts plainly believe Cronos Group is more favorable than Cara Operations.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cara Operations
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Cronos Group
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Cara Operations has higher earnings, but lower revenue than Cronos Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cara OperationsN/AN/AN/AN/AN/A
Cronos GroupC$179.09M9.90-C$32.78MC$0.1925.32

Cronos Group has a net margin of 38.95% compared to Cara Operations' net margin of 0.00%. Cronos Group's return on equity of 6.46% beat Cara Operations' return on equity.

Company Net Margins Return on Equity Return on Assets
Cara OperationsN/A N/A N/A
Cronos Group 38.95%6.46%-3.73%

In the previous week, Cara Operations' average media sentiment score of 0.00 equaled Cronos Group'saverage media sentiment score.

Company Overall Sentiment
Cara Operations Neutral
Cronos Group Neutral

4.3% of Cronos Group shares are held by institutional investors. 46.4% of Cronos Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Cronos Group beats Cara Operations on 8 of the 9 factors compared between the two stocks.

How does Cronos Group compare to Knight Therapeutics?

Cronos Group (TSE:CRON) and Knight Therapeutics (TSE:GUD) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.

Cronos Group has a net margin of 38.95% compared to Knight Therapeutics' net margin of 2.72%. Cronos Group's return on equity of 6.46% beat Knight Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cronos Group38.95% 6.46% -3.73%
Knight Therapeutics 2.72%1.91%0.51%

Cronos Group has a beta of 1.29991, suggesting that its share price is 30% more volatile than the broader market. Comparatively, Knight Therapeutics has a beta of -0.290935, suggesting that its share price is 129% less volatile than the broader market.

4.3% of Cronos Group shares are owned by institutional investors. Comparatively, 22.7% of Knight Therapeutics shares are owned by institutional investors. 46.4% of Cronos Group shares are owned by insiders. Comparatively, 45.6% of Knight Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Cronos Group currently has a consensus price target of C$4.92, indicating a potential upside of 2.22%. Knight Therapeutics has a consensus price target of C$9.50, indicating a potential downside of 5.85%. Given Cronos Group's higher possible upside, equities research analysts plainly believe Cronos Group is more favorable than Knight Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cronos Group
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Knight Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Knight Therapeutics has higher revenue and earnings than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cronos GroupC$179.09M9.90-C$32.78MC$0.1925.32
Knight TherapeuticsC$547.31M1.81-C$30.73MC$0.1567.27

In the previous week, Knight Therapeutics had 1 more articles in the media than Cronos Group. MarketBeat recorded 1 mentions for Knight Therapeutics and 0 mentions for Cronos Group. Cronos Group's average media sentiment score of 0.00 equaled Knight Therapeutics'average media sentiment score.

Company Overall Sentiment
Cronos Group Neutral
Knight Therapeutics Neutral

Summary

Cronos Group beats Knight Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Cronos Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRON and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRON vs. The Competition

Export
MetricCronos GroupPharmaceuticals IndustryHealthcare SectorTSE Exchange
Market CapC$1.78BC$12.60BC$7.31BC$12.84B
Dividend YieldN/A2.63%2.52%6.27%
P/E Ratio25.32792.28274.0840.36
Price / Sales9.90862.22638.219.35
Price / Cash1.6788.6477.8082.29
Price / Book1.6110.5910.474.69
Net Income-C$32.78MC$2.81BC$3.49BC$299.09M
7 Day Performance1.91%-0.11%-0.67%0.01%
1 Month Performance1.48%-1.34%-3.17%-2.14%
1 Year Performance28.95%2.86%15.14%20.17%

Cronos Group Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRON
Cronos Group
1.2957 of 5 stars		C$4.81
-0.2%		C$4.92
+2.2%		+32.1%C$1.78BC$179.09M25.32610
APHA
Aphria
N/AN/AN/AN/AC$5.24BC$611.06MN/A1,200
BHC
Bausch Health Companies
0.6146 of 5 stars		C$7.92
-0.8%		N/A-13.7%C$2.98BC$10.85BN/A20,300
MJN
Cronos Group
N/AC$12.15
-1.9%		N/A+0.0%C$1.73BN/AN/A7,600
CARA
Cara Operations
N/AN/AN/AN/AC$1.62BN/AN/A80

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:CRON) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners
How to get a stake in Anthropic — before the IPO
Anthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...
Weiss Ratings | Sponsoredtc pixel
If you keep cash in a U.S. bank account… read this NOW
Since 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...
Banyan Hill Publishing | Sponsoredtc pixel
Why I believe the AI market will split in Q4
Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...
The Oxford Club | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
On October 7th, your “safest” assets are at risk
Jeff Brown called Nvidia's rise of over 27,000 percent and warned in early 2024 that inflation would outlast W...
Brownstone Research | Sponsoredtc pixel
While SpaceX Gets the Spotlight, FJET Is Building What Comes Next!
Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...
Trading Wire | Sponsoredtc pixel
The REAL Reason 2,000 Missiles Rained on Iran
Two private meetings with U.S. Congressmen and weeks of research point to a surprising explanation for the rec...
Behind the Markets | Sponsoredtc pixel
This free guide explains options the way they should be taught
Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...
Base Camp Trading | Sponsoredtc pixel